For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists ... - PR Newswire (press release)

For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists ... PR Newswire (press release) The report also finds that patient cost-sharing for rheumatoid arthritis drugs does not pose a significant barrier to treatment for patients in France, ... and more »

Incyte Achieves Million Milestone as Novel JAK1 and JAK2 Inhibitor ... - MarketWatch (press release)

Proactive Investors USA & Canada

Incyte Achieves Million Milestone as Novel JAK1 and JAK2 Inhibitor ... MarketWatch (press release) This Phase IIb clinical trial is a global, dose-ranging, study expected to involve 270 patients with active rheumatoid arthritis and is open to enrollment ... Incyte Earns M Milestone from Lilly on Start of Phase IIb Trial with RA ...Genetic Engineering News all 17 news articles »

Zalicus: Ridiculously Cheap - Seeking Alpha

Zalicus: Ridiculously Cheap Seeking Alpha Zacks anticipates management will progress Synavive into a phase II program in rheumatoid arthritis in 2011. If successfully commercialized, Synavive should ...

CORRECT: NICE Not Minded To OK Merck's Simponi, Wants More Data - Wall Street Journal

CORRECT: NICE Not Minded To OK Merck's Simponi, Wants More Data Wall Street Journal However, we strongly believe that people living with rheumatoid arthritis deserve to have as many effective treatment options open to them as possible when ... NHS needs more data on rheumatoid arthritis drugWebMD.Boots.com UK NICE Appraisal Consultation on Merck & Co's Simponi for rheumatoid ...The Pharma Letter (subscription) all 8 news articles »